LON:IMMImmuPharma Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ImmuPharma PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 14 +0.18 (+1.30 %) (As of 08/14/2020 04:00 PM ET) Add Compare Share Today's Range 13.33Now: GBX 14▼ 14.4050-Day Range 12.25MA: GBX 13.86▼ 15.6552-Week Range 0.13Now: GBX 14▼ 32.29Volume508,768 shsAverage Volume817,845 shsMarket Capitalization£25.62 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartCompetitorsEarningsHeadlines ImmuPharma plc, a pharmaceutical company, develops drug candidates based on peptide therapeutics to treat serious medical conditions. The company's lead product candidate is the Lupuzor, which has completed Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists; and the development of peptides as glucagon antagonists to treat type I and type II diabetes; and a clinical development collaboration agreement with Incanthera Limited for Nucant cancer programme. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for ImmuPharma. Previous Next 3.1 Community Rank Outperform VotesImmuPharma has received 266 “outperform” votes. (Add your “outperform” vote.)Underperform VotesImmuPharma has received 164 “underperform” votes. (Add your “underperform” vote.)Community SentimentImmuPharma has received 61.86% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ImmuPharma and other stocks. Vote “Outperform” if you believe IMM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IMM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldImmuPharma does not currently pay a dividend.Dividend GrowthImmuPharma does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ImmuPharma insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of ImmuPharma is -3.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImmuPharma is -3.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmuPharma has a P/B Ratio of 4.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.62 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:IMM Previous Symbol CUSIPN/A CIKN/A Webwww.immupharma.org Phone+44-20-71524080Debt Debt-to-Equity Ratio0.51 Current Ratio6.73 Quick Ratio3.90Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£77,925.00 Price / Sales328.80 Cash FlowGBX 0.81 per share Price / Cash Flow17.19 Book ValueGBX 3.10 per share Price / Book4.52Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees10 Outstanding Shares183,011,008Market Cap£25.62 million Next Earnings DateN/A OptionableNot Optionable GBX 14 +0.18 (+1.30 %) (As of 08/14/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive IMM News and Ratings via Email Sign-up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter. ImmuPharma (LON:IMM) Frequently Asked Questions How has ImmuPharma's stock price been impacted by COVID-19? ImmuPharma's stock was trading at GBX 10.76 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IMM shares have increased by 30.1% and is now trading at GBX 14. View which stocks have been most impacted by COVID-19. How were ImmuPharma's earnings last quarter? ImmuPharma PLC (LON:IMM) released its quarterly earnings data on Thursday, April, 30th. The company reported ($3.99) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($2.90) by $1.09. View ImmuPharma's earnings history. Has ImmuPharma been receiving favorable news coverage? Headlines about IMM stock have been trending neutral recently, according to InfoTrie. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ImmuPharma earned a daily sentiment score of 0.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about ImmuPharma. Who are some of ImmuPharma's key competitors? Some companies that are related to ImmuPharma include Cocrystal Pharma (COCP), Cocrystal Pharma (COCP), 22nd Century Group (XXII), Predictive Technology Group (PRED), OKYO Pharma (OKYO), Acasti Pharma (ACST), Redx Pharma (REDX), AquaBounty Technologies (AQB), Navidea Biopharmaceuticals (NAVB), Novoheart (NVH), Oxford Biodynamics (OBD), Navidea Biopharmaceuticals (NAVB), Omega Diagnostics Group (ORPH), Orthocell (OCC) and Cynata Therapeutics (CYP). View all competitors. What other stocks do shareholders of ImmuPharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuPharma investors own include Castleton Technology (CTP), MOTIF BIO PLC/S (MTFB), Legendary Investments (LEG), Richland Resources (RLD), Sound Energy (SOU), THOR MINI/PAR VTG FPD 0.0001 (THR), Acacia Mining (ACA), Aminex (AEX), Alcatel Lucent (ALU) and DARA Biosciences (DARA). Who are ImmuPharma's key executives? ImmuPharma's management team includes the following people: Mr. Dimitri F. Dimitriou, Co-Founder, CEO & Director (Age 57)Dr. D. Robert Henri Zimmer M.D., Ph.D., Co-Founder, Pres, Chief Scientific Officer & Director (Age 71)Ms. Tracy Weimar BA, MBA, VP of Operations & Fin. and Company Sec.Dr. Jean-Marie Geiger PharmD, MD, Head of Clinical Devel. What is ImmuPharma's stock symbol? ImmuPharma trades on the London Stock Exchange (LON) under the ticker symbol "IMM." How do I buy shares of ImmuPharma? Shares of IMM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is ImmuPharma's stock price today? One share of IMM stock can currently be purchased for approximately GBX 14. How big of a company is ImmuPharma? ImmuPharma has a market capitalization of £25.62 million and generates £77,925.00 in revenue each year. ImmuPharma employs 10 workers across the globe. What is ImmuPharma's official website? The official website for ImmuPharma is www.immupharma.org. How can I contact ImmuPharma? ImmuPharma's mailing address is 50 Broadway, LONDON, SW1H 0BL, United Kingdom. The company can be reached via phone at +44-20-71524080. This page was last updated on 8/15/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
